Oncology Drug Insights by OmicsX
No Result
View All Result
  • Login
  • Register
PRICING
SUBSCRIBE
No Result
View All Result
Oncology Drug Insights by OmicsX
No Result
View All Result
Home Big Pharma

AbbVie, Inc. –
Oncology Drug Pipeline Insights – June 2021

New Oncology Molecules Development Strategy

Team OmicsX by Team OmicsX
May 30, 2022
in Big Pharma, Onco Pipeline Insights, Oncology
495
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

AbbVie is a research-based biopharma company, developing small molecules and biologics for the treatment of various diseases.
In 2013, Abbott Laboratories splits into two entities- Abbott, Inc., to market medical and diagnostic products and AbbVie, Inc. the research and development focused biopharma company.

Global Oncology Intelligence Global Oncology Intelligence

Support authors and subscribe to content

This is premium stuff. Subscribe to read the entire article.

Login if you have purchased

Subscribe

Gain access to over 500+ Updated Articles covering Market Research & Analysis on Drug Development.
Subscribe

Buy Single Article

Unlock this Article and Gain Permanent Access to Read it.
Purchase This Article
Tags: AbbVie
Previous Post

Hoffmann-La Roche –
Oncology Drug Pipeline Insights – June 2021

Next Post

Amgen, Inc.
Oncology Drug Pipeline Analysis – June 2021

Next Post
Amgen, Inc.  Oncology Drug Pipeline Analysis – June 2021

Amgen, Inc.
Oncology Drug Pipeline Analysis - June 2021

Developed by OmicsX. The entirety of this site is protected by copyright © 2025 HH BioTechnologies Private Ltd.

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

*By registering into our website, you agree to the Terms & Conditions and Privacy Policy.
All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result

Developed by OmicsX. The entirety of this site is protected by copyright © 2025 HH BioTechnologies Private Ltd.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?